On the stock market since 2021, it operates in the world of health and science. It has 113 employees. Now — the numbers.
The company is still in the product-building phase: its spending runs far above its sales. That only changes once the product starts selling at scale.
Before the clock runs out, either sales must climb sharply or new money must come in. For now, time is on the company’s side.
Executives buying with their own money is usually read as confidence in the company’s future.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
The price isn’t cheap next to earnings — that’s why this grade sits in the middle.
Clearly below the class average.
Price Momentum: The stock has lagged the market in recent months; investor interest is weak right now.
Business Quality: Profit power and business quality trail similar companies in the sector.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: Right now the product sells for less than it costs to make; every sale deepens the loss.
An investor who bought at the very peak is down 74% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
Sales run at $10M a year. A small number, but proof the product has real buyers.
There is $966.6M in the vault; even if every debt were paid off, $944.4M would remain.
Over the last 12 months, company executives reported 33 buys and 18 sells. Management buying with its own money is usually read as a good sign.
A loss of $113.6M against $10M in annual sales. And on top of that, sales fell from the year before.
This stock swings about 2.5 times as much as the market average. Big rallies — and big drops — can both happen fast.
On our five-subject report card, JANX sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: JANX is a high-risk stock — not yet profitable, and its future rides on its product catching on.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.
Analysts’ average target sits above today’s price, yet the valuation grade (56/100) says the stock isn’t cheap.